Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g 4 Regulatory News (MAV4)

Share Price Information for Maven I&g 4 (MAV4)

Share Price is delayed by 15 minutes
Get Live Data
50.00    0.00 (0.00%)
Bid:
49.00
Ask:
51.00
Spread: 2.00 (4.082%)
Market Cap: £83.71m
MAV4 Live PriceLast checked at - London Stock Exchange

Intraday Maven I&g 4 Share Chart

Possible Merger

13 Sep 2018 18:16

RNS Number : 7504A
Maven Income & Growth VCT 4 PLC
13 September 2018
Β 

Maven Income and Growth VCT 4 PLC

Maven Income and Growth VCT 2 PLC

Β 

13 September 2018

Β 

Possible merger of Maven Income and Growth VCT 4 PLC ("Maven VCT 4") and Maven Income and Growth VCT 2 PLC ("Maven VCT 2") (together the "Companies")

The boards of directors of the Companies announce that they have entered into discussions regarding a possible merger of the Companies (the "Merger"). These discussions may or may not lead to an agreement to merge the Companies. If the Merger is to proceed, the current intention is that it will be undertaken by way of a scheme of reconstruction under s.110 of the Insolvency Act 1986 by transferring the assets and liabilities of Maven VCT 2 to Maven VCT 4 in consideration for the issue of new ordinary shares in Maven VCT 4 to the Maven VCT 2 shareholders on a relative net asset value basis. A merger solely on this basis would be outside the provisions of The City Code on Takeovers and Mergers.

If the Merger is to proceed, it will require formal approval from the shareholders of both Companies. If the Merger is approved, it is expected to achieve costs savings through the establishment of a larger combined fund.

If the Merger proceeds, it is anticipated that the Prospectus and Circulars required under the Listing Rules and companies legislation would be despatched to shareholders in October 2018, with shareholder general meetings taking place in early November 2018, and completion in mid-November 2018.

A further announcement will be made in due course.

The information contained within this announcement is deemed by the Companies to constitute inside information as stipulated under the Market Abuse Regulations (EU number. 596/2014). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

For additional information, please contact:

Maven Capital Partners UK LLP

Secretary to the Companies

Telephone: 0141 306 7400

E-mail: enquiries@mavencp.com

Β 

13 September 2018

Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
MSCGGUUGBUPRGMW
Date   Source Headline
17th Apr 202512:56 pmRNSPublication of Suppl.Prospcts
7th Apr 20257:00 amRNSIssue of Equity - Replacement
4th Apr 20256:18 pmRNSIssue of Equity
2nd Apr 20255:58 pmRNSAnnual Financial Report
1st Apr 20255:05 pmRNSDirectorate Change
1st Apr 202512:59 pmRNSStatement re Offers for Subscription - Closed
27th Mar 20251:12 pmRNSDirector/PDMR Shareholding
27th Mar 20251:07 pmRNSIssue of Equity
27th Mar 202510:25 amRNSUpdate re: Offers for Subscription
18th Mar 20254:10 pmRNSTransaction in Own Shares
14th Mar 202511:58 amRNSUnaudited NAV and Proposed Final Dividend
19th Feb 202510:20 amRNSDirector/PDMR Shareholding
19th Feb 202510:19 amRNSDirector/PDMR Shareholding
19th Feb 202510:18 amRNSDirector/PDMR Shareholding
19th Feb 202510:11 amRNSIssue of Equity
28th Jan 202512:15 pmRNSStatement re Offer for Subscription
28th Jan 202510:42 amRNSIssue of Equity
24th Jan 202511:34 amRNSNet Asset Value(s)
27th Dec 20249:21 amRNSDirector Declaration
10th Dec 20244:08 pmRNSTransaction in Own Shares
26th Nov 20244:20 pmRNSNet Asset Value(s)
14th Nov 20242:55 pmRNSResult of General Meeting
18th Oct 20249:33 amRNSDirector/PDMR Shareholding
18th Oct 20249:29 amRNSIssue of Equity
15th Oct 20249:06 amRNSStatement re Dividend Investment Scheme
27th Sep 20244:31 pmRNSPublication of a Prospectus
18th Sep 202411:09 amRNSHalf-year Report
2nd Sep 20244:55 pmRNSTransaction in Own Shares
23rd Aug 20242:52 pmRNSStatement re NAV and Interim Dividend
24th May 202410:02 amRNSDirector/PDMR Shareholding
24th May 20249:58 amRNSIssue of Equity - Dividend Investment Scheme
15th May 20244:18 pmRNSTransaction in Own Shares
15th May 20242:17 pmRNSNet Asset Value - Dividend Investment Scheme
9th May 20242:35 pmRNSResult of AGM
9th May 20242:28 pmRNSUnaudited Net Asset Value
1st May 202410:08 amRNSIssue of Equity
19th Apr 202412:17 pmRNSIssue of Supplementary Prospectus
5th Apr 20243:48 pmRNSIssue of Equity
27th Mar 202410:39 amRNSIssue of Equity
25th Mar 202410:14 amRNSStatement re Offer for Subscription
19th Mar 20245:03 pmRNSTransaction in Own Shares
20th Feb 20242:48 pmRNSDividend Declaration
8th Feb 202410:33 amRNSDirector/PDMR Shareholding
8th Feb 202410:10 amRNSIssue of Equity
17th Jan 202410:03 amRNSDirector/PDMR Shareholding
17th Jan 202410:02 amRNSDirector/PDMR Shareholding
17th Jan 20249:58 amRNSIssue of Equity
15th Jan 20244:28 pmRNSUnaudited Net Value Asset
15th Nov 20235:06 pmRNSTransaction in Own Shares
9th Nov 20233:53 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.